Rep. Kuster Applauds Legislation to Lower Prescription Drug Costs
Washington, DC, September 19, 2019
Today, Congresswoman Annie Kuster (NH-02) applauded her Democratic colleagues in the House for introducing H.R. 3, the Lower Drug Costs Now Act. Rep. Kuster has joined as a co-sponsor of the bill, which would significantly lower the price of prescription drugs in the United States by enabling the federal government to directly negotiate drug prices for Medicare and the entire U.S. health system. As a member of the House Energy and Commerce Committee’s Health Subcommittee, Rep. Kuster will take part in a hearing on this legislation next week on Wednesday, September 25.
“I continue to hear from Granite Staters who are anxious and worried about being able to afford their medications as the cost of prescription drugs continues to rise,” said Rep. Kuster. “This legislation is part of our commitment to making drugs more affordable. No American should be forced to make the impossible choice between medications they need and necessities like groceries or rent. I’m proud to support this commonsense and much-needed legislation, and I will continue my efforts to ensure all Americans can access quality, affordable health care.”
The Lower Drug Costs Now Act will:
Rep. Kuster has been a long-time proponent of lowering the cost of prescription drugs and has called for legislation to allow Medicare to negotiate directly with pharmaceutical companies to reduce prescription drug prices. In May at an Energy and Commerce Subcommittee hearing, Kuster questioned Dr. Mark Miller, Executive Vice President of Health Care at Arnold Ventures, about the impact greater transparency in drug pricing and direct negotiation by Medicare would have on the affordability of prescription drugs. Kuster has made clear the need to make improvements to the Affordable Care Act (ACA) and has put forward solutions to improve access to affordable health care. Her legislation, the Protecting Americans with Preexisting Conditions Act, passed in the House of Representatives with bipartisan support in May.